ZelosDx provides a low‑cost blood test that isolates peripheral monocytes containing brain‑derived proteins and nucleic acids, offering a surrogate "brain biopsy" for monitoring active neurodegeneration. The assay works with standard phlebotomy samples from humans and animal models and delivers quantitative biomarker data that researchers can use to track disease progression and evaluate drug efficacy.
Funding
$255.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases and brain trauma affect millions of patients, yet research and drug development lack affordable, minimally invasive tools to measure active brain pathology. Existing biomarkers require invasive brain biopsies or expensive imaging, limiting the ability to monitor disease progression and evaluate therapeutic candidates.
Solution
ZelosDx offers a blood‑based assay that isolates peripheral blood phagocytes, which have ingested brain‑derived debris during neurodegeneration. By detecting disease‑specific proteins and nucleic acids within these short‑lived cells, the platform provides a surrogate “brain biopsy” that reflects recent neuronal damage. The assay is low‑cost, requires only a standard blood draw, and can be applied to both human samples and animal models. Results are generated through a proprietary analytical pipeline that quantifies brain‑derived biomarkers, enabling researchers to track active neurodegeneration and assess drug efficacy more efficiently.
Target Audience
Primary customers are academic and pharmaceutical research laboratories developing neurodegenerative disease therapeutics, as well as biotech companies conducting preclinical and clinical biomarker studies.
Features
- Utilizes peripheral blood monocytes as an enriched source of brain‑derived biomarkers, capturing recent neurodegenerative activity
- Proprietary “Window into the Brain™” technology patented in the US, Canada, and Europe
- Minimal sample volume and standard phlebotomy workflow suitable for high‑throughput screening
- Compatible with both human clinical samples and preclinical animal model blood
- Quantitative readout of protein and nucleic acid biomarkers linked to multiple neurodegenerative disease states
- Data output formatted for integration with existing research pipelines and statistical analysis tools